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Background and Aims: Multiple studies have demonstrated the efﬁ  cacy of aminosalicylates 
in maintaining remission in ulcerative colitis (UC). A newer formulation of mesalamine can be 
administered once daily. We aimed to examine the efﬁ  cacy and tolerability of pH-dependent 
mesalamine for long-term maintenance, and compare the rates of medication consumption 
between groups over a prolonged period.
Methods: Subjects whose UC had been quiescent for at least 4 months, and who had been 
receiving mesalamine for maintenance only, were randomized to once daily or conventional 
dosing for 12 months. Disease activity and medication consumption was assessed every 3 months. 
The primary endpoint was the percentage of those with quiescent disease at 12 months.
Results: We enrolled 20 patients, 12 to once daily and 8 to conventional dosing. Six of the 
12 patients (50%) in the once daily group compared with 5 of the 8 patients (62.5%) in the 
conventional group experienced a ﬂ  are (p = 0.31). Only 5 of the 12 (42%) patients in the once 
daily group were adherent compared with 3 of 8 patients (37.5%) in the conventional dosing 
group (p = NS). Median amount consumed in the once daily group was 63% (range 0%–100%) 
and in the conventional group 55% (range 0%–100%), (p  0.5). None of the adherent subjects 
in the once daily group experienced a ﬂ  are, while 6 out of 7 (86%) who were non-adherent 
experienced a ﬂ  are (p  0.01). In the conventional dosing group, 1 in 3 adherent patients (33%) 
experienced a ﬂ  are compared with 4 out of 5 (80%) in the non-adherent group (p  0.01).
Conclusion: Adherence, rather than medication regimen, appeared to be important in disease 
outcome at 12 months.
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Background
Ulcerative colitis (UC) is an idiopathic, chronic inﬂ  ammatory disease of the large 
intestine characterized by episodes of relapse and remission. Relapses are often not 
predictable, although factors such as smoking cessation (Silversetein et al 1994; Fraga 
et al 1997), chronic non-steroidal anti-inﬂ  ammatory use (Evans et al 1997; Felder et al 
2000) and psychological stress (Levenstein et al 2000) are thought to cause symptom 
exacerbation in some individuals.
Multiple studies have demonstrated the efﬁ  cacy of aminosalicylates in maintaining 
remission in UC (Mesalamine Study Group 1996; Ardizzone et al 1995; Fockers et al 
1995; Green et al 1998; Miner et al 1995; Kamm et al 2008). Because of the chronic 
nature of this disease, therapy must often continue indeﬁ  nitely. Many patients openly 
admit that they do not take their medications as prescribed; medication-taking makes 
patients more uncomfortably aware of their chronic illness status, they have a fear of 
long-term side effects from medications, and they question the need for medication 
to treat quiescent disease (Ediger et al 2007).Patient Preference and Adherence 2008:2 254
Kane et al
Previous work done at the University of Chicago 
demonstrated that using objective pharmacy data, rather than 
patient-derived information, the prevalence of medication 
non-adherence was 60% in patients with quiescent UC (Kane 
et al 2001). The average amount of medication consumed was 
70% of that prescribed. In a prospective study, those patients 
who were non-adherent with medications had a higher risk of 
relapse than those who consumed greater than 80% of their 
prescribed regimen (Kane et al 2003).
It is difﬁ  cult to get patients to take medication when they 
feel well, because the rationale for continued use remains 
unclear to them. The long-term goals of improving adher-
ence are to reduce frequency of relapse, lower the incidence 
of long-term complications (ie, colon cancer), and lower 
overall health costs. Simplifying the medication regimen is 
one means to increase adherence.
Recently the FDA approved a new formulation of 
mesalamine to be administered once daily (Kamm et al 2007; 
Lichtenstein et al 2007). Very good adherence rates were 
demonstrated, but these rates were gained during controlled 
trials, rather than in the real world.
A previous short-term pilot trial by this author 
demonstrated safety and efficacy of pH-dependent 
mesalamine (Asacol®, Procter and Gamble Pharmaceuticals, 
Cincinnati Ohio) given once daily, compared with 
conventional dosing (Kane et al 2003). The aim of this study 
was to test this hypothesis in a larger number of patients 
for a longer period of time. We also wished to compare the 
rates of medication consumption between groups over a 
prolonged period of time.
Methods
Patients
Adult patients over the age of 18 treated at one of two practices 
were eligible. Patients must have had documentation of ulcer-
ative colitis by standard criteria, and be in remission for at least 
4 months before study entry. Remission for this study was 
deﬁ  ned clinically, as the absence of all of: blood in the stools, 
urgency, or cramping. Patients must have been prescribed a 
regimen of pH-dependent mesalamine (Asacol®), to maintain 
quiescent disease. Exclusion criteria included documented 
disease activity in the past 4 months, hospitalization or 
steroid use for disease activity in the previous 4 months, the 
use of other preparations of 5-aminosalicylates to treat UC, 
or the use of other immunomodulators to induce remission. 
Patients with a history of other diarrheal illnesses such as diar-
rhea-predominant Irritable Bowel Syndrome, or Clostridium 
difﬁ  cile colitis, or who were using known diarrheal drugs were 
excluded. Before enrollment, the pharmacy of the potential 
subject was contacted and queried about reﬁ  ll information 
to establish adherence to previously prescribed mesalamine. 
Those found to be taking less than 80% of prescribed doses 
were also excluded.
Protocol
The informed consent of eligible patients was obtained (signed 
agreement) before participation. As part of the consent process, 
the updated phone number of the patient’s pharmacy was 
noted. Patients were then randomized to one of two groups: 
once daily or conventional (twice daily or three times daily) 
therapy. Randomization was via the use of opaque sealed enve-
lopes, which contained the assignment based on a computer-
generated randomization table. Subjects were instructed to 
conceal their regimen from all research investigators.
Patients were followed prospectively and assessed 
at 3-month intervals from enrollment. The 3-month and 
9-month checks were via telephone contact by one of the 
study personnel. Disease assessment using the modiﬁ  ed 
Ulcerative Colitis Disease Activity Index (UCDAI) index 
was performed by personnel in a standard fashion (Appen-
dix A). At time intervals of 6 and 12 months, patients were 
assessed during a scheduled clinic visit, using the same 
assessment tool along with a physical exam. Remission was 
deﬁ  ned as a score of 3 or less. Disease activity, or a ﬂ  are of 
disease, was deﬁ  ned as a score 3 or an increase of more than 
3 points during the preceding time interval. No additional 
taking of blood or endoscopy were included in the protocol; 
lab work and endoscopy were performed for patient care as 
determined by each treating physician.
Medication consumption rates at months 3, 6, 9, and 
12 were calculated using pharmacy data obtained by telephone 
by study personnel, and the validated formula as described 
by Steiner and colleagues (Steiner et al 1988). Using the 
telephone number supplied by the patient, the pharmacy was 
called to obtain reﬁ  ll information for the previous 3 months. 
Pharmacists were told that the information was part of an 
approved research study, investigating the effectiveness 
of a new regimen of Asacol®. For those patients who used 
a warehouse service, the date of the patient’s request for 
another supply was recorded and used for the calculation.
The end point of the study was disease relapse or the 
12-month study period. An investigator blinded to the subject 
treatment regimen assessed the outcomes and medication 
consumption rates for each group. Patients experiencing 
a ﬂ  are during the study period were treated as deemed 
necessary by their treating physician.Patient Preference and Adherence 2008:2 255
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Statistics
T-testing was used to compare the means between continuous 
variables. Chi-square or Fisher’s exact test were used to 
compare frequencies of events between the two groups. 
Survival analysis was performed to compare relapse rates 
between the two groups. A p value of less than 0.5 was used 
to signify statistical signiﬁ  cance.
A sample size calculation was performed based on the 
results of the previously published pilot study. Assuming 
a 15% true difference between the two groups and 90% 
power, 53 patients would be needed for each group. Because 
this calculation did not take into account any dropouts, the 
potential recruitment goal was 70 per treatment arm.
Approval from institutional and local institutional review 
boards (IRB) was obtained before any patients were enrolled 
in the study.
Results
Twenty patients were randomized between July 2006 and 
May 2007. Recruitment was discontinued at this time as a 
result of the decision by the sponsoring company to proceed 
with a larger, multi-center study of once daily long-term 
maintenance therapy. The characteristics of the subjects are 
listed in Table 1. The groups were well matched and there 
were no statistical differences in characteristics. The median 
length of diagnosis was 6 years in both groups; the majority 
of subjects had pancolitis, and were prescribed 2.4 g of 
mesalamine for maintenance at the time of enrollment. There 
was one death during the study, of a patient randomized to 
the once daily group; the cause of death was cardiac in nature 
and not felt to be related to medication use or UC directly.
Twelve subjects were randomized to once daily 
mesalamine for 12 months and 8 to the conventional dosing 
group. All the patients in the conventional dosing group had 
previously been taking their medication bid, and continued 
to do so during the study. Of the patients from the once 
daily group, 6/12 (50%) experienced a ﬂ  are of disease 
activity (average increase in UCDAI score of 4 points over 
baseline, with a range of 2–7) during the study period com-
pared with 5/8 patients (62.5%) in the conventional group 
(p = 0.31). The median time to ﬂ  are was 8 months (range 
3–11 months).
Only 5/12 (42%) subjects in the once daily group were 
adherent to their regimen compared with 3/8 (37.5%) in the 
conventional dosing group (p  0.05). The median amount 
consumed in the once daily group was 63% (range 0–100%) 
and in the conventional group it was 55% (range 0–100%); 
this was not statistically different (p  0.5).
Of those subjects adherent in the once daily group, 0/5 
experienced a ﬂ  are of disease, while 6/7 (86%) who were 
non-adherent experienced a ﬂ  are of disease (p  0.001). In 
the conventional dosing group, 1/3 adherent patients (33%) 
experienced a ﬂ  are of disease compared with 4/5 (80%) in 
the non-adherent group (p  0.01).
No reported adverse events were felt to be associated 
directly with once daily therapy; medication was well 
tolerated at both once and twice daily administrations. The 
one death that occurred during the study was secondary to 
myocardial infarction in an elderly male patient with a his-
tory of coronary artery disease. The patient had remained in 
remission at the time of death and the investigators did not 
feel that his regimen of mesalamine in any way contributed 
to his death.
Discussion
In this small, randomized cohort of patients, we found that 
long-term adherence was sub-optimal. Adherence ranged from 
0 to 100%, with the median in both groups falling well below 
the accepted 80% needed for adherence. Indeed, disease activ-
ity was signiﬁ  cantly associated with non-adherence regardless 
of prescribed regimen. This result reinforces the principle that 
continued medication consumption, rather than actual drug 
regimen, is important in preventing disease relapse.
The clinical outcomes of nonadherence can be detrimental 
to patients. Researchers have previously shown a correlation 
between poor adherence and increased frequency of relapses. 
In the prospective study of 98 patients with quiescent ulcer-
ative colitis, non-adherent patients were found to have more 
than a 5-fold increased risk of disease relapse compared with 
those who were adherent (Kane et al 2003).
Non-adherence to 5-aminosalicylic acid (5-ASA)-based 
therapy has also been linked to an increased risk of developing 
Table 1 Patient characteristics
Variable Once Daily 
(N = 12)
Conventional 
(N = 8)
p value
Age, median (range) 44 (22–67) 42 (27–58) NS
Sex (%M) 58% 62.5% NS
Length of disease, 
median (range)
6 (2–25) 6 (3–27) NS
Extent
 Pancolitis 9 6 NS
 Left  sided 2 2 NS
 Proctitis 1 0 NS
Dose at enrollment, 
avg (range)
2.4 g 
(1.6–3.2)
2.4 g (1.6–3.2) NSPatient Preference and Adherence 2008:2 256
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colorectal cancer. Moody et al showed a correlation between 
nonadherence to, or discontinuation from, sulfasalazine 
therapy and increased risk of colon cancer (Moody et al 1996). 
Five out of 152 adherent patients and 5 out of 16 nonadherent 
patients developed colorectal cancer (X2 test p  0.001). 
This ﬁ  nding was supported by Eaden et al who showed in a 
case-controlled study (102 cases of colorectal cancer in UC 
with matched controls) that colorectal cancer risk was reduced 
by 81% in patients receiving regular mesalamine (1.2 g/day) 
therapy compared with those taking no treatment (p = 0.006) 
(Eaden et al 2000).
The Manitoba Inﬂ  ammatory Bowel Disease Cohort Study 
also looked at the nature of adherence in patients with either 
Crohn’s disease or UC (Ediger et al 2007). Patients from this 
population-based cohort were queried by postal questionnaire 
on adherence to a range of therapies to treat inﬂ  ammatory 
bowel disease. A total of 35% of patients met the study’s 
criteria for low adherence. Males with UC were signiﬁ  cantly 
more likely to have poor adherence than males with Crohn’s 
disease (p = 0.01). In this study, the investigators found that 
age was a predictive factor for adherence in females; younger 
females were less adherent than older females. Males of all 
ages had comparable levels of adherence and the rate of poor 
adherence in males was broadly similar to that of the older 
women (which was a novel ﬁ  nding and contrasted with the 
results of our previous study where younger males were the 
least adherent).
Other factors contributing to poor adherence in the 
Manitoba Cohort study were heavy pill burden and frequent 
dosing, which are similar ﬁ  ndings to those of previous studies. 
The main factors however, were found to be cost (reported 
by 25% of patients), reinforcement of status as person with a 
disease condition (13%), unpleasant side effects (13%), and 
lack of belief in the effectiveness of the medication (12%).
It is unclear whether continued enrollment in this trial 
would result in signiﬁ  cant differences in outcome or adher-
ence rates between treatment regimens. We saw a signiﬁ  cant 
number of disease ﬂ  ares during this study, but it is unclear 
whether the inclusion criterion of only 4 months of remission 
prior to enrollment was too short. The larger maintenance 
registration trials did not require this length of remission, 
which again suggests that it may be adherence, in the real 
world versus controlled trials, that drives improved long-term 
outcomes. The maintenance study of once or twice daily 
MMX mesalazine did not ﬁ  nd any signiﬁ  cant differences in 
adherence rates between dosing regimens (Kamm et al 2008), 
but adherence was measured with pill count rather than in a 
more real world setting as in this study. We did not attempt 
any pill counts as patients were seen only every 6 months, 
and thus it would have been impractical to use this as another 
means to measure adherence.
The observed tolerability and continued efﬁ  cacy of once 
daily pH-dependent mesalamine encouraged the manufac-
turers after enrollment of 20 patients to undertake a larger, 
national trial of once daily Asacol® for the maintenance 
treatment of ulcerative colitis. We did not feel that there 
were any ethical issues that needed to be addressed with early 
termination of this study, as patients were being treated with 
an approved medication and the regimen, not the therapy, 
was under investigation. These patients were offered enroll-
ment into the larger multi-center trial when the protocol was 
approved by respective local IRBs.
Because of the documented safety of once or twice daily 
mesalamine from this and other trials, changing a patient’s 
regimen to once or twice daily seems an appropriate strategy 
to increase adherence. More importantly however, is patient 
education on the relationship of continued medication con-
sumption and improved outcomes.
In conclusion, in this small cohort of patients, a pH-
dependent formulation of mesalamine is associated with 
continued disease control if consumed on a regular basis, 
regardless of daily regimen. Ongoing patient education is key 
to optimizing long-term outcomes; simplifying regimens is 
not sufﬁ  cient to guarantee prolonged quiescent disease.
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Appendix A
Ulcerative Colitis Disease Activity Index
1) No. liquid or verysoft stools per day:  _____
2) Abdominal pain, sum of 7 daily ratings:  _____
    (0  = none, 1 = mild, 2 = moderate, 3 = severe)
3) General well-being:  _____
    (0  = very well, 1 = slightly below par, 2 = poor, 3 = very poor, 4 = terrible)
4) Complications: (score 1 point per item)
 Joint  pains  _____
  Skin or mouth ulcers  _____
  Eye redness or inﬂ  ammation  _____
 Anal  ﬁ  ssure  _____
5) Bleeding per rectum:  _____
    (0  = none, 1 = slight, 2 = moderate, 3 = severe)
Score: _______